Next Article in Journal
First DNA Sequencing in Beninese Indigenous Cattle Breeds Captures New Milk Protein Variants
Previous Article in Journal
Somatic Mosaicism and Autism Spectrum Disorder
Article

Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis

Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
*
Author to whom correspondence should be addressed.
Academic Editor: Peixin Dong
Received: 29 August 2021 / Revised: 22 October 2021 / Accepted: 25 October 2021 / Published: 26 October 2021
(This article belongs to the Special Issue MicroRNAs as Biomarkers and Therapeutic Targets in Disease)
Gemcitabine is the first-line treatment for patients with pancreatic cancer (PC), yet most patients develop resistance to gemcitabine. Recent studies showed that circular RNAs (circRNAs) have important regulatory roles in PC progression and chemoresistance. In this study, the ability of circRNA circ_0092367 to enhance gemcitabine efficacy was tested and the underlying molecular mechanism of circ_0092367 was investigated. The expression levels of circ_0092367, miR-1206, and ESRP1 were measured using qRT-PCR experiments. The effects of circ_0092367, miR-1206, and ESRP1 on PC cell lines exposed to gemcitabine were examined by CCK-8 assays. We performed luciferase assays to determine the relationship between circ_0092367 and miR-1206 and between miR-1206 and ESRP1. We demonstrated that circ_0092367 was significantly downregulated in PC tissues and cell lines, and a high expression of circ_0092367 was associated with improved survival in patients with PC. Gain- and loss-of-function assays revealed that circ_0092367 inhibited epithelial–mesenchymal transition (EMT) phenotypes and sensitized PC cells to gemcitabine treatment in vitro and in vivo. Cytoplasmic circ_0092367 could directly repress the levels of miR-1206 and thus upregulate the expression of ESRP1, thereby inhibiting EMT and enhancing the sensitivity of PC cells to gemcitabine treatment. Our findings show that circ_0092367 plays a crucial role in sensitizing PC cells to gemcitabine by modulating the miR-1206/ESRP1 axis, highlighting its potential as a valuable therapeutic target in PC patients. View Full-Text
Keywords: circular RNA; gemcitabine; EMT; pancreatic cancer circular RNA; gemcitabine; EMT; pancreatic cancer
Show Figures

Figure 1

MDPI and ACS Style

Yu, S.; Wang, M.; Zhang, H.; Guo, X.; Qin, R. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis. Genes 2021, 12, 1701. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12111701

AMA Style

Yu S, Wang M, Zhang H, Guo X, Qin R. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis. Genes. 2021; 12(11):1701. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12111701

Chicago/Turabian Style

Yu, Shuo, Min Wang, Hang Zhang, Xingjun Guo, and Renyi Qin. 2021. "Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis" Genes 12, no. 11: 1701. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12111701

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop